PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsClomipramine
Clomipramine
Anafranil, Clomipramine (clomipramine) is a small molecule pharmaceutical. Clomipramine was first approved as Anafranil on 1989-12-29. It is used to treat depressive disorder, obsessive-compulsive disorder, pain, panic disorder, and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent dopamine transporter, G protein-activated inward rectifier potassium channel 4, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
mental disordersD001523
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Anafranil, Clomipramine (discontinued: Clomipramine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clomipramine hydrochloride
Tradename
Company
Number
Date
Products
ANAFRANILSPECGXN-019906 RX1989-12-29
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
anafranilNew Drug Application2023-11-29
clomipramine hclANDA2023-12-29
clomipramine hydrochlorideANDA2024-10-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
panic disorderEFO_0004262D016584F41.0
psychotic affective disorders—D000341F39
obsessive-compulsive disorderEFO_0004242D009771F42
depressive disorderEFO_1002014D003866F32.A
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AA: Non-selective monoamine reuptake inhibitors
— N06AA04: Clomipramine
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863—F33.92—12611
Obsessive-compulsive disorderD009771EFO_0004242F42—12249
Compulsive personality disorderD003193—F60.5—12249
Depressive disorderD003866EFO_1002014F32.A———257
Major depressive disorderD003865EFO_0003761F22———134
Treatment-resistant depressive disorderD061218—————112
AtrophyD001284—————1—1
Panic disorderD016584EFO_0004262F41.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature birthD047928EFO_0003917O60—21——3
Premature ejaculationD061686HP_0012876F52.4—21——3
DementiaD003704EFO_0003862F03——1——1
Psychophysiologic disordersD011602—F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Somatoform disordersD013001—F45——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Back painD001416HP_0003418M54—2———2
SciaticaD012585HP_0011868M54.3—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
MalnutritionD044342EFO_0008572E40-E461————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Taste disordersD013651——————33
Drug-related side effects and adverse reactionsD064420—T88.7————11
Drug interactionsD004347——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameClomipramine
INNclomipramine
Description
Clomipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. It has a role as a serotonergic antagonist, a serotonergic drug, a serotonin uptake inhibitor, an EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor, an antidepressant and an anticoronaviral agent. It is functionally related to an imipramine. It is a conjugate base of a clomipramine(1+).
Classification
Small molecule
Drug classantidepressants (imipramine type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
Identifiers
PDB—
CAS-ID303-49-1
RxCUI—
ChEMBL IDCHEMBL415
ChEBI ID47780
PubChem CID2801
DrugBankDB01242
UNII IDNUV44L116D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Clomipramine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,775 documents
View more details
Safety
Black-box Warning
Black-box warning for: Anafranil, Clomipramine hcl, Clomipramine hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,184 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use